skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Daclizumab (Code C1569)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Daclizumab

Definition: A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway.

NCI-GLOSS Definition: A monoclonal antibody that is being studied in the treatment of adult T-cell leukemia and in the treatment of cytopenia (low blood cell count).

Display Name: Daclizumab

Label: Daclizumab

NCI Thesaurus Code: C1569 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0663182  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-Tac Humanized Monoclonal Antibody
Anti-Tac Monoclonal Antibody
Humanized Anti-Tac Monoclonal Antibody
Monoclonal Antibody Anti-Tac

External Source Codes: 
CAS Registry Number 152923-56-3 (see NLM ChemIDplus info)
NSC Code 725173 (see NCI DTP info)
PDQ Closed Trial Search ID 42006
PDQ Open Trial Search ID 42006 (check for NCI PDQ open clinical trial info)
UMLS CUI C0663182

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Kidney transplant rejection, prevention
code C1569
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Daclizumab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom